Search research articles
Contact Us
Filters
Showing results (191-200 of 297) with videos related to
Page
of 30
Sort By:
Scientific Reports
|
December 12, 2023
Heavy-chain antibody targeting of CD38 NAD<sup>+</sup> hydrolase ectoenzyme to prevent fibrosis in multiple organs
Bo Shi, Asif Amin, Pranjali Dalvi, et al.
American Journal of Respiratory Cell and Molecular Biology
|
April 2, 2011
Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation
Anna P Lam, Annette S Flozak, Susan Russell, et al.
Journal of Psychosomatic Research
|
October 18, 2020
Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study
Brett D Thombs, Linda Kwakkenbos, Richard S Henry, et al.
American Journal of Respiratory Cell and Molecular Biology
|
September 27, 2016
Lrp5/β-Catenin Signaling Controls Lung Macrophage Differentiation and Inhibits Resolution of Fibrosis
Joseph A Sennello, Alexander V Misharin, Annette S Flozak, et al.
Journal of Scleroderma and Related Disorders
|
June 24, 2024
Physical activity during COVID-19 in people with systemic sclerosis: A Scleroderma Patient-centred Intervention Network COVID-19 Cohort longitudinal study
Amanda Wurz, Richard S Henry, Linda Kwakkenbos, et al.
Clinical and Experimental Rheumatology
|
July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)
Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
JCI Insight
|
February 1, 2022
PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis
Dan Xu, Swati Bhattacharyya, Wenxia Wang, et al.
JCI Insight
|
July 13, 2018
TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung
Swati Bhattacharyya, Wenxia Wang, Wenyi Qin, et al.
Clinical Rheumatology
|
December 11, 2008
Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects
Zoltán Szekanecz, Magdolna Aleksza, Péter Antal-Szalmás, et al.
The Lancet. Rheumatology
|
January 30, 2024
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study
Yvonne C Lee, Rina S Fox, Linda Kwakkenbos, et al.
Page
of 30
Search research articles
Search
Showing results (191-200 of 297) with videos related to
Sort By:
Page
of 30
Scientific Reports
|
December 12, 2023
Heavy-chain antibody targeting of CD38 NAD<sup>+</sup> hydrolase ectoenzyme to prevent fibrosis in multiple organs
Bo Shi, Asif Amin, Pranjali Dalvi, et al.
American Journal of Respiratory Cell and Molecular Biology
|
April 2, 2011
Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation
Anna P Lam, Annette S Flozak, Susan Russell, et al.
Journal of Psychosomatic Research
|
October 18, 2020
Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study
Brett D Thombs, Linda Kwakkenbos, Richard S Henry, et al.
American Journal of Respiratory Cell and Molecular Biology
|
September 27, 2016
Lrp5/β-Catenin Signaling Controls Lung Macrophage Differentiation and Inhibits Resolution of Fibrosis
Joseph A Sennello, Alexander V Misharin, Annette S Flozak, et al.
Journal of Scleroderma and Related Disorders
|
June 24, 2024
Physical activity during COVID-19 in people with systemic sclerosis: A Scleroderma Patient-centred Intervention Network COVID-19 Cohort longitudinal study
Amanda Wurz, Richard S Henry, Linda Kwakkenbos, et al.
Clinical and Experimental Rheumatology
|
July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)
Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
JCI Insight
|
February 1, 2022
PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis
Dan Xu, Swati Bhattacharyya, Wenxia Wang, et al.
JCI Insight
|
July 13, 2018
TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung
Swati Bhattacharyya, Wenxia Wang, Wenyi Qin, et al.
Clinical Rheumatology
|
December 11, 2008
Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects
Zoltán Szekanecz, Magdolna Aleksza, Péter Antal-Szalmás, et al.
The Lancet. Rheumatology
|
January 30, 2024
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study
Yvonne C Lee, Rina S Fox, Linda Kwakkenbos, et al.
Page
of 30